Estrella Immunopharma Inc

For the period ended Jun 30, 2024. Filed Sep 27, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Sep 27, 2024

ESLA$0.51+36.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

As of June 30, 2024 · As of June 30, 2023
Assets
Current assets:
Cash and cash equivalent		$4,165,428	$2,479,146
Prepaid expenses and other receivable		288,761	-
Extension note receivable		-	273,066
Total current assets		4,454,189	2,752,212
Other Assets
Deferred transaction costs		-	276,187
Total Assets		$4,454,189	$3,028,399
Liabilities, Preferred Stock and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable - related party	$	-	$9,333,146
Other payables and accrued liabilities		131,823	398,781
Accrued liability - related party		4,000	22,000
Franchise tax payables		4,134	4,297
Income tax payables		40,744	-
Total current liabilities		180,701	9,758,224
Non-current liabilities:
Other liability		-	12,725
Total non-current liabilities		-	12,725
Total Liabilities		180,701	9,770,949
Commitments and Contingencies (Note 7)
Preferred Stock*
Series A Preferred Stock, $0.0001 par value, 15,000,000 shares authorized;		-	5,000,000
0 and 1,203,695 shares issued and outstanding as of June 30, 2024 and 2023, respectively
Series AA Preferred Stock, $0.0001 par value, 105,000,000 shares authorized;		-	-
0 and 25,277,591 shares issued and outstanding as of June 30, 2024 and 2023, respectively
Stockholders’ Equity (Deficit):
Common stock, $0.0001 par value; 250,000,000 shares authorized;
36,610,870 and 978,243 shares issued as of June 30, 2024 and 2023, respectively*		3,661	98
Additional paid-in capital		24,124,543	445,905
Accumulated deficit		(19,500,276)	(12,188,553)
Treasury stock, at cost 321,794 and 0 shares as of June 30, 2024 and 2023, respectively		(354,440)	-
Total Stockholders’ Equity (Deficit)		4,273,488	(11,742,550)
Total Liabilities, Preferred Stock and Stockholders’ Equity (Deficit)		$4,454,189	$3,028,399

*	Giving retroactive effect to reverse recapitalization effected on September 29, 2023 to reflect exchange ratio of approximately 0.2407 as described in Note 3

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.